Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 12/2011

01-12-2011 | Original article

Effect of the simultaneous administration of glucocorticoids and IL-15 on human NK cell phenotype, proliferation and function

Authors: Ardiana Moustaki, Kimon V. Argyropoulos, Constantin N. Baxevanis, Michael Papamichail, Sonia A. Perez

Published in: Cancer Immunology, Immunotherapy | Issue 12/2011

Login to get access

Abstract

We have previously reported a synergistic effect between hydrocortisone (HC) and IL-15 on promoting natural killer (NK) cell expansion and function. In the present study, we extend our findings to methylprednisolone (MeP) and dexamethasone (Dex), thus ascribing to glucocorticoids (GCs) a general feature as positive regulators of IL-15-mediated effects on NK cells. We demonstrate that each GC when combined with IL-15 in cultures of peripheral blood (PB)-derived CD56+ cells induces increased expansion of CD56+CD3 cells displaying high cytolytic activity, IFN-γ production potential and activating receptor expression, including NKp30, NKp44, NKp46, 2B4, NKG2D and DNAM-1. Furthermore, GCs protected NK cells from IL-15-induced cell death. The combination of IL-15 with GCs favored the expansion of a relatively more immature CD16low/neg NK cell population, with high expression of NKG2A and CD94, and significantly lower expression of KIR (CD158a and CD158b) and CD57, compared to IL-15 alone. IL-15-expanded NK cells, in the presence or absence of GCs, did not express CD62L, CXCR1 or CCR7. However, the presence of GCs significantly increased the density of CXCR3 and induced strong CXCR4 expression on the surface of NK cells. Our data indicate that IL-15/GC-expanded NK cells, apart from their increased proliferation rate, retain their functional integrity and exhibit a migratory potential rendering them useful for adoptive transfer in NK cell-based cancer immunotherapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Papamichail M, Perez SA, Gritzapis AD, Baxevanis CN (2004) Natural killer lymphocytes: biology, development, and function. Cancer Immunol Immunother 53:176–186PubMedCrossRef Papamichail M, Perez SA, Gritzapis AD, Baxevanis CN (2004) Natural killer lymphocytes: biology, development, and function. Cancer Immunol Immunother 53:176–186PubMedCrossRef
2.
go back to reference Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9:503–510PubMedCrossRef Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9:503–510PubMedCrossRef
3.
go back to reference Farag SS, Caligiuri MA (2006) Human natural killer cell development and biology. Blood Rev 20:123–137PubMedCrossRef Farag SS, Caligiuri MA (2006) Human natural killer cell development and biology. Blood Rev 20:123–137PubMedCrossRef
4.
go back to reference Sun JC, Lopez-Verges S, Kim CC, Derisi JL, Lanier LL (2011) NK cells and immune “memory”. J Immunol 186:1891–1897PubMedCrossRef Sun JC, Lopez-Verges S, Kim CC, Derisi JL, Lanier LL (2011) NK cells and immune “memory”. J Immunol 186:1891–1897PubMedCrossRef
5.
go back to reference Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA (2001) Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97:3146–3151PubMedCrossRef Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA (2001) Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97:3146–3151PubMedCrossRef
6.
go back to reference Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, Buckley CD, McMichael A, Enver T, Bowness P (2007) CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol 179:89–94PubMed Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, Buckley CD, McMichael A, Enver T, Bowness P (2007) CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol 179:89–94PubMed
7.
go back to reference Bjorkstrom NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, Bjorklund AT, Flodstrom-Tullberg M, Michaelsson J, Rottenberg ME, Guzman CA, Ljunggren HG, Malmberg KJ (2010) Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 116:3853–3864PubMedCrossRef Bjorkstrom NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, Bjorklund AT, Flodstrom-Tullberg M, Michaelsson J, Rottenberg ME, Guzman CA, Ljunggren HG, Malmberg KJ (2010) Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 116:3853–3864PubMedCrossRef
8.
go back to reference Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, Norris PJ, Nixon DF, Lanier LL (2010) CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 116:3865–3874PubMedCrossRef Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, Norris PJ, Nixon DF, Lanier LL (2010) CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 116:3865–3874PubMedCrossRef
9.
go back to reference Arai S, Klingemann HG (2005) Natural killer cells: can they be useful as adoptive immunotherapy for cancer? Expert Opin Biol Ther 5:163–172PubMedCrossRef Arai S, Klingemann HG (2005) Natural killer cells: can they be useful as adoptive immunotherapy for cancer? Expert Opin Biol Ther 5:163–172PubMedCrossRef
10.
go back to reference Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051–3057PubMedCrossRef Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051–3057PubMedCrossRef
11.
go back to reference Ashwell JD, Lu FW, Vacchio MS (2000) Glucocorticoids in T cell development and function*. Annu Rev Immunol 18:309–345PubMedCrossRef Ashwell JD, Lu FW, Vacchio MS (2000) Glucocorticoids in T cell development and function*. Annu Rev Immunol 18:309–345PubMedCrossRef
12.
go back to reference Rook GA (1999) Glucocorticoids and immune function. Baillieres Best Pract Res Clin Endocrinol Metab 13:567–581PubMedCrossRef Rook GA (1999) Glucocorticoids and immune function. Baillieres Best Pract Res Clin Endocrinol Metab 13:567–581PubMedCrossRef
13.
go back to reference Cohen JJ, Duke RC (1984) Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J Immunol 132:38–42PubMed Cohen JJ, Duke RC (1984) Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J Immunol 132:38–42PubMed
14.
go back to reference Herold MJ, McPherson KG, Reichardt HM (2006) Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 63:60–72PubMedCrossRef Herold MJ, McPherson KG, Reichardt HM (2006) Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 63:60–72PubMedCrossRef
15.
go back to reference Perandones CE, Illera VA, Peckham D, Stunz LL, Ashman RF (1993) Regulation of apoptosis in vitro in mature murine spleen T cells. J Immunol 151:3521–3529PubMed Perandones CE, Illera VA, Peckham D, Stunz LL, Ashman RF (1993) Regulation of apoptosis in vitro in mature murine spleen T cells. J Immunol 151:3521–3529PubMed
16.
go back to reference Almawi WY, Beyhum HN, Rahme AA, Rieder MJ (1996) Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol 60:563–572PubMed Almawi WY, Beyhum HN, Rahme AA, Rieder MJ (1996) Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol 60:563–572PubMed
17.
go back to reference Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G (1992) A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci USA 89:9991–9995PubMedCrossRef Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G (1992) A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci USA 89:9991–9995PubMedCrossRef
18.
go back to reference Bischof F, Melms A (1998) Glucocorticoids inhibit CD40 ligand expression of peripheral CD4+ lymphocytes. Cell Immunol 187:38–44PubMedCrossRef Bischof F, Melms A (1998) Glucocorticoids inhibit CD40 ligand expression of peripheral CD4+ lymphocytes. Cell Immunol 187:38–44PubMedCrossRef
19.
go back to reference Baus E, Andris F, Dubois PM, Urbain J, Leo O (1996) Dexamethasone inhibits the early steps of antigen receptor signalling in activated T lymphocytes. J Immunol 156:4555–4561PubMed Baus E, Andris F, Dubois PM, Urbain J, Leo O (1996) Dexamethasone inhibits the early steps of antigen receptor signalling in activated T lymphocytes. J Immunol 156:4555–4561PubMed
20.
go back to reference Zacharchuk CM, Mercep M, Chakraborti PK, Simons SS Jr, Ashwell JD (1990) Programmed T lymphocyte death. Cell activation- and steroid-induced pathways are mutually antagonistic. J Immunol 145:4037–4045PubMed Zacharchuk CM, Mercep M, Chakraborti PK, Simons SS Jr, Ashwell JD (1990) Programmed T lymphocyte death. Cell activation- and steroid-induced pathways are mutually antagonistic. J Immunol 145:4037–4045PubMed
21.
go back to reference Franchimont D, Galon J, Vacchio MS, Fan S, Visconti R, Frucht DM, Geenen V, Chrousos GP, Ashwell JD, O’Shea JJ (2002) Positive effects of glucocorticoids on T cell function by up-regulation of IL-7 receptor alpha. J Immunol 168:2212–2218PubMed Franchimont D, Galon J, Vacchio MS, Fan S, Visconti R, Frucht DM, Geenen V, Chrousos GP, Ashwell JD, O’Shea JJ (2002) Positive effects of glucocorticoids on T cell function by up-regulation of IL-7 receptor alpha. J Immunol 168:2212–2218PubMed
22.
go back to reference Wiegers GJ, Labeur MS, Stec IE, Klinkert WE, Holsboer F, Reul JM (1995) Glucocorticoids accelerate anti-T cell receptor-induced T cell growth. J Immunol 155:1893–1902PubMed Wiegers GJ, Labeur MS, Stec IE, Klinkert WE, Holsboer F, Reul JM (1995) Glucocorticoids accelerate anti-T cell receptor-induced T cell growth. J Immunol 155:1893–1902PubMed
23.
go back to reference Hinrichs CS, Palmer DC, Rosenberg SA, Restifo NP (2005) Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. J Immunother 28:517–524PubMedCrossRef Hinrichs CS, Palmer DC, Rosenberg SA, Restifo NP (2005) Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. J Immunother 28:517–524PubMedCrossRef
24.
go back to reference Naito M, Itoh K, Komatsu N, Yamashita Y, Shirakusa T, Yamada A, Moriya F, Ayatuka H, Mohamed ER, Matsuoka K, Noguchi M (2008) Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients. Prostate 68:1753–1762PubMedCrossRef Naito M, Itoh K, Komatsu N, Yamashita Y, Shirakusa T, Yamada A, Moriya F, Ayatuka H, Mohamed ER, Matsuoka K, Noguchi M (2008) Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients. Prostate 68:1753–1762PubMedCrossRef
25.
go back to reference Perez SA, Mahaira LG, Demirtzoglou FJ, Sotiropoulou PA, Ioannidis P, Iliopoulou EG, Gritzapis AD, Sotiriadou NN, Baxevanis CN, Papamichail M (2005) A potential role for hydrocortisone in the positive regulation of IL-15-activated NK-cell proliferation and survival. Blood 106:158–166PubMedCrossRef Perez SA, Mahaira LG, Demirtzoglou FJ, Sotiropoulou PA, Ioannidis P, Iliopoulou EG, Gritzapis AD, Sotiriadou NN, Baxevanis CN, Papamichail M (2005) A potential role for hydrocortisone in the positive regulation of IL-15-activated NK-cell proliferation and survival. Blood 106:158–166PubMedCrossRef
26.
go back to reference Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M, Perez SA (2010) A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 59:1781–1789PubMedCrossRef Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M, Perez SA (2010) A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 59:1781–1789PubMedCrossRef
27.
go back to reference Salagianni M, Lekka E, Moustaki A, Iliopoulou EG, Baxevanis CN, Papamichail M, Perez SA (2011) NK Cell adoptive transfer combined with ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. J Immunol 186:3327–3335PubMedCrossRef Salagianni M, Lekka E, Moustaki A, Iliopoulou EG, Baxevanis CN, Papamichail M, Perez SA (2011) NK Cell adoptive transfer combined with ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. J Immunol 186:3327–3335PubMedCrossRef
28.
go back to reference Quah BJ, Warren HS, Parish CR (2007) Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc 2:2049–2056PubMedCrossRef Quah BJ, Warren HS, Parish CR (2007) Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc 2:2049–2056PubMedCrossRef
29.
go back to reference Lecoeur H, Fevrier M, Garcia S, Riviere Y, Gougeon ML (2001) A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J Immunol Methods 253:177–187PubMedCrossRef Lecoeur H, Fevrier M, Garcia S, Riviere Y, Gougeon ML (2001) A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J Immunol Methods 253:177–187PubMedCrossRef
30.
go back to reference Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F, Caligiuri MA (1999) Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 162:4511–4520PubMed Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F, Caligiuri MA (1999) Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 162:4511–4520PubMed
31.
go back to reference Vitale C, Chiossone L, Cantoni C, Morreale G, Cottalasso F, Moretti S, Pistorio A, Haupt R, Lanino E, Dini G, Moretta L, Mingari MC (2004) The corticosteroid-induced inhibitory effect on NK cell function reflects down-regulation and/or dysfunction of triggering receptors involved in natural cytotoxicity. Eur J Immunol 34:3028–3038PubMedCrossRef Vitale C, Chiossone L, Cantoni C, Morreale G, Cottalasso F, Moretti S, Pistorio A, Haupt R, Lanino E, Dini G, Moretta L, Mingari MC (2004) The corticosteroid-induced inhibitory effect on NK cell function reflects down-regulation and/or dysfunction of triggering receptors involved in natural cytotoxicity. Eur J Immunol 34:3028–3038PubMedCrossRef
32.
go back to reference Chiossone L, Vitale C, Cottalasso F, Moretti S, Azzarone B, Moretta L, Mingari MC (2007) Molecular analysis of the methylprednisolone-mediated inhibition of NK-cell function: evidence for different susceptibility of IL-2- versus IL-15-activated NK cells. Blood 109:3767–3775PubMedCrossRef Chiossone L, Vitale C, Cottalasso F, Moretti S, Azzarone B, Moretta L, Mingari MC (2007) Molecular analysis of the methylprednisolone-mediated inhibition of NK-cell function: evidence for different susceptibility of IL-2- versus IL-15-activated NK cells. Blood 109:3767–3775PubMedCrossRef
33.
go back to reference Lanier LL (2008) Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9:495–502PubMedCrossRef Lanier LL (2008) Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9:495–502PubMedCrossRef
34.
go back to reference Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L (2001) Activating receptors and co receptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19:197–223PubMedCrossRef Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L (2001) Activating receptors and co receptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19:197–223PubMedCrossRef
35.
go back to reference Romagnani C, Juelke K, Falco M, Morandi B, D’Agostino A, Costa R, Ratto G, Forte G, Carrega P, Lui G, Conte R, Strowig T, Moretta A, Munz C, Thiel A, Moretta L, Ferlazzo G (2007) CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol 178:4947–4955PubMed Romagnani C, Juelke K, Falco M, Morandi B, D’Agostino A, Costa R, Ratto G, Forte G, Carrega P, Lui G, Conte R, Strowig T, Moretta A, Munz C, Thiel A, Moretta L, Ferlazzo G (2007) CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol 178:4947–4955PubMed
36.
go back to reference Yu J, Mao HC, Wei M, Hughes T, Zhang J, Park IK, Liu S, McClory S, Marcucci G, Trotta R, Caligiuri MA (2010) CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood 115:274–281PubMedCrossRef Yu J, Mao HC, Wei M, Hughes T, Zhang J, Park IK, Liu S, McClory S, Marcucci G, Trotta R, Caligiuri MA (2010) CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood 115:274–281PubMedCrossRef
37.
go back to reference Berahovich RD, Lai NL, Wei Z, Lanier LL, Schall TJ (2006) Evidence for NK cell subsets based on chemokine receptor expression. J Immunol 177:7833–7840PubMed Berahovich RD, Lai NL, Wei Z, Lanier LL, Schall TJ (2006) Evidence for NK cell subsets based on chemokine receptor expression. J Immunol 177:7833–7840PubMed
38.
go back to reference Carson WE, Fehniger TA, Caligiuri MA (1997) CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. Eur J Immunol 27:354–360PubMedCrossRef Carson WE, Fehniger TA, Caligiuri MA (1997) CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. Eur J Immunol 27:354–360PubMedCrossRef
39.
go back to reference Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22:633–640PubMedCrossRef Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22:633–640PubMedCrossRef
40.
go back to reference Perez SA, Sotiropoulou PA, Gkika DG, Mahaira LG, Niarchos DK, Gritzapis AD, Kavalakis YG, Antsaklis AI, Baxevanis CN, Papamichail M (2003) A novel myeloid-like NK cell progenitor in human umbilical cord blood. Blood 101:3444–3450PubMedCrossRef Perez SA, Sotiropoulou PA, Gkika DG, Mahaira LG, Niarchos DK, Gritzapis AD, Kavalakis YG, Antsaklis AI, Baxevanis CN, Papamichail M (2003) A novel myeloid-like NK cell progenitor in human umbilical cord blood. Blood 101:3444–3450PubMedCrossRef
41.
go back to reference Perez SA, Mahaira LG, Sotiropoulou PA, Gritzapis AD, Iliopoulou EG, Niarchos DK, Cacoullos NT, Kavalakis YG, Antsaklis AI, Sotiriadou NN, Baxevanis CN, Papamichail M (2006) Effect of IL-21 on NK cells derived from different umbilical cord blood populations. Int Immunol 18:49–58PubMedCrossRef Perez SA, Mahaira LG, Sotiropoulou PA, Gritzapis AD, Iliopoulou EG, Niarchos DK, Cacoullos NT, Kavalakis YG, Antsaklis AI, Sotiriadou NN, Baxevanis CN, Papamichail M (2006) Effect of IL-21 on NK cells derived from different umbilical cord blood populations. Int Immunol 18:49–58PubMedCrossRef
42.
go back to reference Vitale C, Cottalasso F, Montaldo E, Moretta L, Mingari MC (2008) Methylprednisolone induces preferential and rapid differentiation of CD34+ cord blood precursors toward NK cells. Int Immunol 20:565–575PubMedCrossRef Vitale C, Cottalasso F, Montaldo E, Moretta L, Mingari MC (2008) Methylprednisolone induces preferential and rapid differentiation of CD34+ cord blood precursors toward NK cells. Int Immunol 20:565–575PubMedCrossRef
43.
go back to reference Grzywacz B, Kataria N, Blazar BR, Miller JS, Verneris MR (2011) Natural killer cell differentiation by myeloid progenitors. Blood 117:3548–3558PubMedCrossRef Grzywacz B, Kataria N, Blazar BR, Miller JS, Verneris MR (2011) Natural killer cell differentiation by myeloid progenitors. Blood 117:3548–3558PubMedCrossRef
44.
go back to reference Berg M, Lundqvist A, McCoy P Jr, Samsel L, Fan Y, Tawab A, Childs R (2009) Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 11:341–355PubMedCrossRef Berg M, Lundqvist A, McCoy P Jr, Samsel L, Fan Y, Tawab A, Childs R (2009) Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 11:341–355PubMedCrossRef
45.
go back to reference Huenecke S, Zimmermann SY, Kloess S, Esser R, Brinkmann A, Tramsen L, Koenig M, Erben S, Seidl C, Tonn T, Eggert A, Schramm A, Bader P, Klingebiel T, Lehrnbecher T, Passweg JR, Soerensen J, Schwabe D, Koehl U (2010) IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion. J Immunother 33:200–210PubMedCrossRef Huenecke S, Zimmermann SY, Kloess S, Esser R, Brinkmann A, Tramsen L, Koenig M, Erben S, Seidl C, Tonn T, Eggert A, Schramm A, Bader P, Klingebiel T, Lehrnbecher T, Passweg JR, Soerensen J, Schwabe D, Koehl U (2010) IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion. J Immunother 33:200–210PubMedCrossRef
46.
go back to reference Juelke K, Killig M, Luetke-Eversloh M, Parente E, Gruen J, Morandi B, Ferlazzo G, Thiel A, Schmitt-Knosalla I, Romagnani C (2010) CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood 116:1299–1307PubMedCrossRef Juelke K, Killig M, Luetke-Eversloh M, Parente E, Gruen J, Morandi B, Ferlazzo G, Thiel A, Schmitt-Knosalla I, Romagnani C (2010) CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood 116:1299–1307PubMedCrossRef
47.
go back to reference Beider K, Nagler A, Wald O, Franitza S, Dagan-Berger M, Wald H, Giladi H, Brocke S, Hanna J, Mandelboim O, Darash-Yahana M, Galun E, Peled A (2003) Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood 102:1951–1958PubMedCrossRef Beider K, Nagler A, Wald O, Franitza S, Dagan-Berger M, Wald H, Giladi H, Brocke S, Hanna J, Mandelboim O, Darash-Yahana M, Galun E, Peled A (2003) Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood 102:1951–1958PubMedCrossRef
48.
go back to reference Curnow SJ, Wloka K, Faint JM, Amft N, Cheung CM, Savant V, Lord J, Akbar AN, Buckley CD, Murray PI, Salmon M (2004) Topical glucocorticoid therapy directly induces up-regulation of functional CXCR4 on primed T lymphocytes in the aqueous humor of patients with uveitis. J Immunol 172:7154–7161PubMed Curnow SJ, Wloka K, Faint JM, Amft N, Cheung CM, Savant V, Lord J, Akbar AN, Buckley CD, Murray PI, Salmon M (2004) Topical glucocorticoid therapy directly induces up-regulation of functional CXCR4 on primed T lymphocytes in the aqueous humor of patients with uveitis. J Immunol 172:7154–7161PubMed
49.
go back to reference Wendel M, Galani IE, Suri-Payer E, Cerwenka A (2008) Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 68:8437–8445PubMedCrossRef Wendel M, Galani IE, Suri-Payer E, Cerwenka A (2008) Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 68:8437–8445PubMedCrossRef
50.
go back to reference Burger JA, Kipps TJ (2006) CXCR4: a key receptor in the crosstalk between tumour cells and their microenvironment. Blood 107:1761–1767PubMedCrossRef Burger JA, Kipps TJ (2006) CXCR4: a key receptor in the crosstalk between tumour cells and their microenvironment. Blood 107:1761–1767PubMedCrossRef
51.
go back to reference Muller V, Alix-Panabieres C, Pantel K (2010) Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. Eur J Cancer 46:1189–1197PubMedCrossRef Muller V, Alix-Panabieres C, Pantel K (2010) Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. Eur J Cancer 46:1189–1197PubMedCrossRef
Metadata
Title
Effect of the simultaneous administration of glucocorticoids and IL-15 on human NK cell phenotype, proliferation and function
Authors
Ardiana Moustaki
Kimon V. Argyropoulos
Constantin N. Baxevanis
Michael Papamichail
Sonia A. Perez
Publication date
01-12-2011
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 12/2011
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-011-1067-6

Other articles of this Issue 12/2011

Cancer Immunology, Immunotherapy 12/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine